Novo Signs $2.6B Hengrui Deal, Presents Semaglutide 2 mg Data
Novo Nordisk has licensed HRS-1596, a Phase 1-ready oral GLP-1/GIP dual agonist from Hengrui Pharma, in a deal worth up to $2.6 billion, while new real-world data linked semaglutide 2 mg with a lower risk of major adverse cardiovascular events than switching to tirzepatide



